Pharmaceutical manufacturers of Epo

Sun Pharma is a global, comprehensive, specialized pharmaceutical company with production facilities for API and FDF in India, the United States, Latin America, and Europe. It produces and sells a wide range of pharmaceutical formulations as branded generics and generic drugs in India, the US, and various other global markets. It is supported by 2 advanced R&D Centers with a team of over 600 scientists for projects in Chemical Synthesis, Clinical Research, and formulation development. Sun is a frontrunner in specific therapy areas and possesses robust expertise in product development, process chemistry, and manufacturing.

Pfizer CentreOne® is a completely distinct global contract development and manufacturing organization (CDMO), as well as a prominent provider of specialty APIs and intermediates. Supported by resources from Pfizer, we have provided technical knowledge, regulatory assistance, and long-term supply for more than 40 years. With a network of over 35 sites spanning six continents, we are capable of securely and effectively guiding complex compounds from development to commercial manufacture. For more details, please visit http://www.pfizercentreone.com

Euroapi focuses on revolutionizing active component solutions to sustainably fulfill the demands of clients and patients globally. As a prominent figure in active pharmaceutical ingredients, we possess a comprehensive portfolio of around 200 products, encompassing a wide range of technologies, and are constantly developing innovative molecules through our Contract Development and Manufacturing Organization (CDMO). Our 3,350 employees are driven by the commitment to improving access to essential therapies and promoting health

Veranova boasts over 50 years of expertise and is a frontrunner in the creation and fabrication of intricate and specialized APIs for the pharmaceutical and biotech sectors. It was previously a segment of Johnson Matthey, specializing in intricate and regulated chemical processes. The company delivers customized services throughout all phases of drug development and is split into Generics and Originators. It possesses a variety of development technologies and areas of expertise, along with a cooperative approach to API manufacturing and procedures.

Recipharm is an experienced, global CDMO dedicated to meeting your evolving needs through operational excellence, scientific know-how and customer connectivity. Our worldwide reach, localised market knowledge and ever-expanding alliance of expertise allow us to anticipate your needs and provide tailored, reliable services to consistently deliver on time and in full.

Formed through the fusion of Farmabios, Novasep, and PharmaZell, Axplora stands out as a principal manufacturer of active pharmaceutical ingredients (APIs), ensuring the timely and scalable delivery of high-quality compounds. With a collective proficiency and a diverse production capacity spanning 9 industrial facilities, incorporating specialized technologies such as Hazardous Chemistry, Chromatography, ADCs, Steroids, Continuous Processes, Lipids, and HPAPIs, Axplora provides dependable and flexible solutions: CDMO services for small molecule APIs and biopharmaceuticals to both innovators and generic API Products. We, at Axplora, are committed to unifying Farmabios, Novasep, and PharmaZell, establishing ourselves as a top-tier API manufacturer dedicated to serving the foremost patient-focused pharmaceutical and biotechnology enterprises, ensuring the reliable and sustainable production of premium active ingredients in adherence to the highest industry standards. Axplora's mission is centered on empowering pharmaceutical companies to enhance the development of vital medications, fostering a faster, safer, and more dependable approach to benefit patients worldwide. Leveraging our combined expertise and manufacturing facilities spread across nine sites in Europe and India, along with a research and development center in the USA, Axplora is positioned to offer comprehensive CDMO solutions.

We, at TIEFENBACHER GROUP, are driven by a deep sense of purpose: we are pioneering healthcare to improve patients’ lives around the world. We believe that the access to affordable high quality-healthcare is a human right. We always challenge the status quo to be one step ahead – in terms of business models as well as concrete products and services. This entrepreneurial spirit is the driving force of making high-quality pharmaceuticals more affordable, more available, and better than before. 100% family owned since 1963, we are a purpose-driven healthcare company providing best-in-class solutions throughout the entire pharmaceutical value chain. From initial idea to market access: We distribute raw materials and develop, manufacture, and register finished dosage forms like tablets, capsules, powders, drops, and patches as well as medical devices. This broad competence enables us to pioneer healthcare holistically as we can connect ideas and expertise to create novel healthcare solutions. By working together as TIEFENBACHER GROUP, in agile collaboration and cross-functional structures, we tap into our full potential and stay at the forefront of our field.

Sai Life Sciences provides advanced Discovery, Contract Development and Manufacturing Solutions, utilizing a wide range of expert capabilities throughout the molecular lifecycle. At Sai Life Sciences, we offer scientific knowledge with a greater mission – to influence the future of healthcare by developing treatments for current incurable ailments. We collaborate with pioneering pharmaceutical and biotech firms to expedite the exploration, creation, and production of intricate small molecules for a healthier future. Our goal is to assist our global innovator partners in bringing 25 new medicines to life by 2025. And we are making significant progress towards that objective.

Zhejiang Huida Biotech Co., Ltd. is situated in Hangzhou, within Zhejiang Province. It was founded in 2020 and operates as a subsidiary of Huadong Medicine Co., Ltd. The organization specializes in the exploration and formulation of microbial active pharmaceutical substances (APIs), intermediates, and extensive health products. It stands as a technologically inventive research enterprise in the field of fermentation products. Leveraging robust R&D capabilities, the corporation delivers top-notch technology, service, and products to its global clientele by uncovering and nurturing the most valuable microbial metabolites.

Everlight Chemical Industrial Co. established in 1972 commenced the development of prostaglandin APIs in 1992. We have attained sustainable expansion through the equilibrium of financial, societal, and environmental accountability as well as ensuring worker's safety. Our APIs have been officially recognized globally, encompassing the US, Canada, UK, EU, Japan, China, Russia, India, South America, Egypt, the Middle East, and more. Our facility holds certifications from the Taiwan FDA, US FDA, EMEA, PMDA, and Swedish MPA. Presently, our sales reach over 40 countries worldwide.